- AU$8.30m
- AU$24.26m
- AU$9.31m
Brief: Cann Group Increases Private Credit Loan Facility By A$2 Million
Brief: Cann Group Says Mike Ryan To Assume Role Of Interim Exec Chair
Brief: Cann Group Anticipates FY2026 Revenue Of A$9.2-A$10 Million
Brief: Cann Group Posts Profit For Half-Year A$26.4 Million
Brief: Cann Group Appointed Mike Ryan As Chairman
Brief: Cann Group Sees FY26 Revenue Of A$17.0 Mln
Brief: Cann Group Seeks Trading Halt
Brief: Cann Group Posts FY Net Loss Attributable A$22.3 Million
New Zealand's Rua Bioscience surges on legal resolution with Australia's Cann Group
Brief: Rua Bioscience Says Co & Cann Reach Resolution In Legal Proceedings
Brief: Cann Group Posts Qtrly Production Of 1.53 Tonnes
Australia's Cann Group hits record low on discounted placement
Brief: Cann Group Seeks Trading Halt
Brief: Cann Group Executes Supply Agreements With Initial 11 Chemist Warehouse Pharmacy Outlets In Queensland
Australia's Cann Group soars on supply agreement with Chemist Warehouse
Brief: Cann Group Posts HY Loss From Ordinary Activities After Tax A$10.7 Million
Brief: Cann Group Says NAB To Extend Maturity Dates Of Construction Loan & Working Capital Facility
Brief: Cann Group Posts Qtrly Sales Revenue (Unaudited) Of A$2.7 Mln
Brief: Cann Group Announces Non- Renounceable Rights Issue To Raise A$6.25 Mln